BRIEF: Hengrui Pharma to raise up to $1.3 billion in Hong Kong IPO
Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) launched its Hong Kong IPO on Thursday, aiming to sell 225 million shares at a price range of HK$41.45 to HK$44.05 per share,…
CStone Finds Tonic in Steady Stream of Drug Approvals, Licensing Deals
Cancer drug specialist reported its first significant revenue in 2020, following a string of milestones capped by a $200 million investment from Pfizer Key takeaways: Strong upfront licensing fees helped…
Recent Articles
RELATED ARTICLES
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
BRIEF: Sany Heavy plans Hong Kong listing to raise up to $1.5 billion
600031.SHG
- BRIEF: Minieye IPO to raise up to $100 million in Hong Kong IPO
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
BRIEF: Guming to raise $220 million in Hong Kong IPO
1364.HK
-
BRIEF: CATL targets $4 billion in Hong Kong IPO, poised to become year’s top listing
300750.SHE
